GSK/Adolor Entereg “Approvable” Pending CV Risk Data
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.